These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17179668)

  • 1. Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate.
    Okamura T; Someya K; Matsuo K; Hasegawa A; Yamamoto N; Honda M
    Microbiol Immunol; 2006; 50(12):989-1000. PubMed ID: 17179668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.
    Someya K; Xin KQ; Matsuo K; Okuda K; Yamamoto N; Honda M
    J Virol; 2004 Sep; 78(18):9842-53. PubMed ID: 15331719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
    Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
    J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.
    Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M
    J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.
    Seth A; Ourmanov I; Schmitz JE; Kuroda MJ; Lifton MA; Nickerson CE; Wyatt L; Carroll M; Moss B; Venzon D; Letvin NL; Hirsch VM
    J Virol; 2000 Mar; 74(6):2502-9. PubMed ID: 10684264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity.
    Yoshino N; Kanekiyo M; Hagiwara Y; Okamura T; Someya K; Matsuo K; Ami Y; Sato S; Yamamoto N; Honda M
    Scand J Immunol; 2008 Nov; 68(5):476-83. PubMed ID: 18803609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors.
    Nakaya Y; Nakaya T; Park MS; Cros J; Imanishi J; Palese P; García-Sastre A
    J Virol; 2004 Sep; 78(17):9366-75. PubMed ID: 15308731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal delivery of recombinant vaccinia virus vector DIs induces gut-mucosal immunity.
    Yoshino N; Kanekiyo M; Hagiwara Y; Okamura T; Someya K; Matsuo K; Ami Y; Sato S; Yamamoto N; Honda M
    Scand J Immunol; 2010 Aug; 72(2):98-105. PubMed ID: 20618768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.
    Uberla K; Rosenwirth B; Ten Haaft P; Heeney J; Sutter G; Erfle V
    J Med Primatol; 2007 Feb; 36(1):2-9. PubMed ID: 17359459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
    Sharpe S; Polyanskaya N; Dennis M; Sutter G; Hanke T; Erfle V; Hirsch V; Cranage M
    J Gen Virol; 2001 Sep; 82(Pt 9):2215-2223. PubMed ID: 11514732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol.
    Someya K; Ami Y; Nakasone T; Izumi Y; Matsuo K; Horibata S; Xin KQ; Yamamoto H; Okuda K; Yamamoto N; Honda M
    J Immunol; 2006 Feb; 176(3):1784-95. PubMed ID: 16424209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
    Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
    J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
    Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
    Doria-Rose NA; Ohlen C; Polacino P; Pierce CC; Hensel MT; Kuller L; Mulvania T; Anderson D; Greenberg PD; Hu SL; Haigwood NL
    J Virol; 2003 Nov; 77(21):11563-77. PubMed ID: 14557642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
    Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
    J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.
    Nilsson C; Mäkitalo B; Berglund P; Bex F; Liljeström P; Sutter G; Erfle V; ten Haaft P; Heeney J; Biberfeld G; Thorstensson R
    Vaccine; 2001 May; 19(25-26):3526-36. PubMed ID: 11348720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
    Hirsch VM; Fuerst TR; Sutter G; Carroll MW; Yang LC; Goldstein S; Piatak M; Elkins WR; Alvord WG; Montefiori DC; Moss B; Lifson JD
    J Virol; 1996 Jun; 70(6):3741-52. PubMed ID: 8648709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.